Anne Wojcicki has been declared the winner of a bankruptcy auction for 23andMe, the genetics testing start-up she founded, ...

The co-founder of bankrupt genetic analysis company 23andMe won an auction for the firm’s assets, agreeing, along with a ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Anne Wojcicki's nonprofit is set to purchase all significant assets of the bankrupt genetic testing company, 23andMe, for ...

This was the stock's second consecutive day of gains.

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped ...

Market Domination Overtime hosts Julie Hyman and Josh Lipton preview the top market stories and headlines Wall Street will be paying attention to tomorrow, Friday, June 13, including June's ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...